Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system

Allain, 2005, Protecting the blood supply from emerging pathogens: the role of pathogen inactivation, Transfusion Medicine Reviews, 19, 110, 10.1016/j.tmrv.2004.11.005

Buchta, 2005, Transfusion-related exposure to the plasticizer di(2-ethylhexyl)phthalate in patients receiving plateletpheresis concentrates, Transfusion, 45, 798, 10.1111/j.1537-2995.2005.04380.x

Burnouf-Radosevich, 1992, Chromatographic preparation of a therapeutic highly purified von Willebrand factor concentrate from human cryoprecipitate, Vox Sanguinis, 62, 1, 10.1111/j.1423-0410.1992.tb01159.x

Burnouf, 2006, A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system, Vox Sanguinis, 91, 56, 10.1111/j.1423-0410.2006.00772.x

Burnouf, 2006, A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable-bag system, Transfusion, 46, 2100, 10.1111/j.1537-2995.2006.01035.x

Burnouf, 2007, Preparation and viral inactivation of cryoprecipitate in blood banks in resource-limited countries, ISBT Science Series, 2, 121, 10.1111/j.1751-2824.2007.00126.x

Burnouf, 2007, Impact of Triton X-100 on alpha 2-antiplasmin (SERPINF2) activity in solvent/detergent-treated plasma, Biologicals, 35, 349, 10.1016/j.biologicals.2007.03.002

Burnouf, 2008, Properties of a concentrated minipool solvent-detergent treated cryoprecipitate processed in single-use bag systems, Haemophilia, 14, 956, 10.1111/j.1365-2516.2008.01797.x

Casleton, 1998, Recovery and viability of Orientia tsutsugamushi from packed red cells and the danger of acquiring scrub typhus from blood transfusion, Transfusion, 38, 680, 10.1046/j.1537-2995.1998.38798346638.x

Chang, 1997, Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities, Thrombosis and Haemostasis, 78, 930, 10.1055/s-0038-1657654

Cohen, 2001, Management of von Willebrand disease: a survey on current clinical practice from the haemophilia centres of North America, Haemophilia, 7, 235, 10.1046/j.1365-2516.2001.00498.x

Cole, 1981, Contamination of commercial blood products by di-2-ethylhexyl phthalate and mono-2-ethylhexyl phthalate, Vox Sanguinis, 40, 317, 10.1111/j.1423-0410.1981.tb00715.x

Farrugia, 2004, Choice of replacement therapy for hemophilia-cryoprecipitate issues: a rebuttal, Journal of Thrombosis and Haemostasis, 2, 1022, 10.1111/j.1538-7836.2004.00702.x

Favaloro, 1997, Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease, Pathology, 29, 385, 10.1080/00313029700169365

Federici, 1998, Optimizing therapy with factor VIII/von Willebrand factor concentrates in von Willebrand disease, Haemophilia, 4, 7, 10.1046/j.1365-2516.1998.0040s3007.x

Fricke, 1989, Characterization of von Willebrand factor in factor VIII concentrates, American Journal of Hematology, 31, 41, 10.1002/ajh.2830310108

Hoffman, 1987, Fibrinogen content of low-volume cryoprecipitate, Transfusion, 27, 356, 10.1046/j.1537-2995.1987.27487264748.x

Horowitz, 1985, Inactivation of viruses in labile blood derivatives. I. Disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations., Transfusion, 25, 516, 10.1046/j.1537-2995.1985.25686071422.x

Horowitz, 1992, Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma, Blood, 79, 826, 10.1182/blood.V79.3.826.826

Inoue, 2005, Evaluation and analysis of exposure levels of di(2-ethylhexyl) phthalate from blood bags, Clinica Chimica Acta, 358, 159, 10.1016/j.cccn.2005.02.019

Kasper, 2005, Products for clotting factor replacement in developing countries, Seminars in Thrombosis and Hemostasis, 31, 507, 10.1055/s-2005-922221

Keeling, 1997, Cryoprecipitate prepared from plasma virally inactivated by the solvent detergent method, British Journal of Haematology, 96, 194, 10.1046/j.1365-2141.1997.d01-1993.x

Khaisuwan, 2001, Transmission of scrub typhus by blood transfusion?, Transfusion, 41, 1454, 10.1046/j.1537-2995.2001.41111454.x

Klein, 2005, Pathogen inactivation technology: cleansing the blood supply, Journal of Internal Medicine, 257, 224, 10.1111/j.1365-2796.2005.01451.x

Loff, 2000, Polyvinylchloride infusion lines expose infants to large amounts of toxic plasticizers, Journal of Pediatric Surgery, 35, 1775, 10.1053/jpsu.2000.19249

Mannucci, 1994, Biochemical characteristics of therapeutic plasma concentrates used in the treatment of von Willebrand disease, Haemostasis, 24, 285

Marshall, 1978, Commercial fibrinogen, autogenous plasma, whole blood and cryoprecipitate for coagulum pyelolithotomy: a comparative study, The Journal of Urology, 119, 310, 10.1016/S0022-5347(17)57473-X

Mazurier, 2004, In vitro study of a triple-secured von Willebrand factor concentrate, Vox Sanguinis, 86, 100, 10.1111/j.0042-9007.2004.00398.x

Michalski, 1988, Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma, Vox Sanguinis, 55, 202, 10.1111/j.1423-0410.1988.tb04698.x

Ness, 1979, Cryoprecipitate as a reliable source of fibrinogen replacement, JAMA, 241, 1690, 10.1001/jama.1979.03290420016016

Pereira, 2007, Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection, Haematologica, 92, 846, 10.3324/haematol.11072

Prowse, 2009, Properties of pathogen-inactivated plasma components, Transfusion Medicine Reviews, 23, 124, 10.1016/j.tmrv.2008.12.004

Rentas, 2007, Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model, Transfusion, 47, 240, 10.1111/j.1537-2995.2007.01094.x

Segura, 2009, Assessment of the impact of solvent/detergent treatment on the quality and potency of a whole IgG equine antivenom, Biologicals, 10.1016/j.biologicals.2009.05.003

Solheim, 2008, Pathogen reduction of blood components, Transfusion and Apheresis Science, 39, 75, 10.1016/j.transci.2008.05.003

Srivastava, 1999, Factor replacement for haemophilia–should cryoprecipitate be used?, Haemophilia, 5, 301, 10.1046/j.1365-2516.1999.00337.x

Srivastava, 2003, Factor replacement therapy in haemophilia–are there models for developing countries?, Haemophilia, 9, 391, 10.1046/j.1365-2516.2003.00766.x

Turecek, 2002, Comparative study on collagen-binding enzyme-linked immunosorbent assay and ristocetin cofactor activity assays for detection of functional activity of von Willebrand factor, Seminars in Thrombosis and Hemostasis, 28, 149, 10.1055/s-2002-27817

Van Voorhis, 2003, Trypanosoma cruzi inactivation in human platelet concentrates and plasma by a psoralen (amotosalen HCl) and long-wavelength UV, Antimicrobial Agents and Chemotherapy, 47, 475, 10.1128/AAC.47.2.475-479.2003

WHO. (2003) Guidelines on Viral Inactivation and Removal Procedures Intended to Assure the Viral Safety of Human Blood Plasma Products. Geneva. URL www.WHO.int/bloodproducts.

WHO. (2005) Recommendations for the Production, Quality Control and Regulation of Plasma for Fractionation. URL http://www.who.int/bloodproducts.